Prospective Longitudinal Cohort Study of Implant Age, Pocket Plane, Incision, Surface Texture, and Volume as Predictors of Breast Implant Rupture
1 other identifier
observational
3,000
1 country
1
Brief Summary
This prospective dynamic cohort will follow women with intact aesthetic silicone breast implants to evaluate predictors of rupture. Implant age, pocket plane, incision route, surface texture, and volume will be recorded, and participants will undergo annual clinical and imaging surveillance for up to five years. Confirmed rupture will require MRI or operative evidence. Delayed-entry survival models will estimate the independent association of implant and surgical characteristics with rupture risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 12, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2026
CompletedFirst Submitted
Initial submission to the registry
September 2, 2026
CompletedFirst Posted
Study publicly available on registry
September 9, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2026
ExpectedSeptember 9, 2026
September 1, 2026
12 years
September 2, 2026
September 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to First Confirmed Breast Implant Rupture
Implant-level time from cohort entry to the first MRI- or surgically confirmed full-thickness implant shell rupture. Implant age is used as the survival time scale with delayed entry at age on enrollment. Contralateral implants are accounted for by patient-level clustering.
From cohort entry through years of prospective follow-up. 10 TO 12 YEARS
Secondary Outcomes (1)
Rupture-Free Survival by Implant Age
12 YEARS
Study Arms (1)
Aesthetic Breast Implant Surveillance Cohort
Women with intact silicone implants at enrollment are followed prospectively. Pocket plane, incision, texture, volume, and implant age are modeled as exposures rather than recruitment groups.
Interventions
Implant-level exposure data include implantation date, laterality, pocket plane, incision route, surface texture, shape, volume, manufacturer/lot when available, primary versus revision placement, and concomitant mastopexy or fat grafting. Linked arm/group(s): Intact Aesthetic Breast Implant Surveillance Cohort.
Baseline and annual high-resolution ultrasound will assess implant integrity. Suspicious or indeterminate findings will undergo MRI according to the locked diagnostic algorithm. Rupture is confirmed by MRI, operative inspection, or both. Linked arm/group(s): Intact Aesthetic Breast Implant Surveillance Cohort.
Eligibility Criteria
Adult women with aesthetic silicone breast implants documented as intact at cohort entry, including new implant recipients and prevalent implant carriers.
You may qualify if:
- Female sex and age 18 years or older.
- Aesthetic breast augmentation with permanent silicone implants.
- Known implantation date or sufficiently precise implantation year, pocket plane, incision route, surface texture, and implant volume.
- Both implants or the analyzed implant documented as intact at baseline by the study imaging algorithm.
- Ability to complete annual surveillance for up to five years.
- Written informed consent.
You may not qualify if:
- Reconstructive implantation after mastectomy, congenital deformity, or major trauma.
- Tissue expander or nonpermanent device.
- Confirmed rupture at cohort entry for the implant under analysis.
- PIP implant or another recalled device if the final protocol elects to exclude it from etiologic modeling.
- Missing core implant characteristics or implantation date.
- Planned immediate explantation or exchange at enrollment for a reason unrelated to surveillance.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Research Inclead
Study Sites (1)
IQ interquirofanos
Medellín, Colombia
Related Publications (4)
Hadad E, Sualhi I, Legarda C, Seligman Y, Sorkin A, Dor O, Menashe S, Heller L, Wiser I. Silicone breast implant rupture is more prevalent in the dominant limb side: A retrospective cohort study. J Plast Reconstr Aesthet Surg. 2023 May;80:126-132. doi: 10.1016/j.bjps.2023.02.016. Epub 2023 Feb 20.
PMID: 37011442BACKGROUNDPaolini G, Firmani G, Briganti F, Macino M, Nigrelli S, Sorotos M, Santanelli di Pompeo F. Assessment of Risk Factors for Rupture in Breast Reconstruction Patients with Macrotextured Breast Implants. Aesthetic Plast Surg. 2023 Apr;47(2):517-530. doi: 10.1007/s00266-022-03118-9. Epub 2022 Oct 13.
PMID: 36229658BACKGROUNDHadad E, Klein D, Seligman Y, Wiser I, Heller L. Sub-muscular plane for augmentation mammoplasty patients increases silicone gel implant rupture rate. J Plast Reconstr Aesthet Surg. 2019 Mar;72(3):419-423. doi: 10.1016/j.bjps.2018.11.009. Epub 2018 Nov 22.
PMID: 30616906BACKGROUNDGlener AD, Sergesketter AR, Adams WP Jr. Outcomes of In-Office, High Resolution Ultrasound Silicone Breast Implant Surveillance by Plastic Surgeons. Aesthet Surg J. 2024 Dec 12;45(1):48-55. doi: 10.1093/asj/sjae165.
PMID: 39054844BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
juan velez, MD, plastic surgery
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 2, 2026
First Posted
September 9, 2026
Study Start
January 12, 2014
Primary Completion
January 1, 2026
Study Completion (Estimated)
December 15, 2026
Last Updated
September 9, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share
not contempled in the patient informed concent